Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK1.40
-0.04 (-2.78%)
DK STO Healthcare Biotechnology
Address
SCION-DTU Science Park 2970
Horsholm, DK
Horsholm, DK
CEO
Bent U. Frandsen
Website
expres2ionbio.com
IPO
2016-07-29
ISIN SE0023261292
Description
Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK1.40
-0.04 (-2.78%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
97.6K
Beta
2.16
Float Shares
2.55M
Free Float %
95.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -8.56% | -20.81% | -89.13% | -89.24% | -90.15% | -92.73% | -99.03% | -99.89% | -99.22% | -99.22% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.40
DCF (Unlevered)
14.07
+904.8%
DCF (Levered)
10.15
+625.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.78
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+21.4% ★ Q1'26: -22.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+4.5% Q1'26: +77.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,445.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,444.4% Q1'26: -1,712.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -971.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.6% Q1'26: +344.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.26M
est: 16.00M (-67.1%)
|
12.23M
est: 12.50M (-2.1%)
|
5.09M
est: 6.00M (-15.2%)
|
7.05M
est: 8.75M (-19.4%)
|
3.01M
est: 7.50M (-59.8%)
|
3.66M
est: 9.00M (-59.4%)
|
7.30M
7.30M – 7.30M
-18.9% YoY
|
11.80M
11.80M – 11.80M
+61.6% YoY
|
14.10M
14.10M – 14.10M
+19.5% YoY
|
9.00M
9.00M – 9.00M
-36.2% YoY
|
| EBITDA |
-28.47M
est: -16.00M (-78.0%)
|
-46.38M
est: -12.50M (-271.0%)
|
-124.49M
est: -6.00M (-1,974.9%)
|
-102.45M
est: -8.75M (-1,070.9%)
|
-64.34M
est: -7.50M (-757.9%)
|
-51.35M
est: -9.00M (-470.6%)
|
-7.30M
-7.30M – -7.30M
+18.9% YoY
|
-11.80M
-11.80M – -11.80M
-61.6% YoY
|
-14.10M
-14.10M – -14.10M
-19.5% YoY
|
-9.00M
-9.00M – -9.00M
+36.2% YoY
|
| EBIT |
-31.39M
est: -16.00M (-96.2%)
|
-48.19M
est: -12.50M (-285.5%)
|
-125.71M
est: -6.00M (-1,995.2%)
|
-104.05M
est: -8.75M (-1,089.2%)
|
-67.70M
est: -7.50M (-802.6%)
|
-52.82M
est: -9.00M (-486.9%)
|
-7.30M
-7.30M – -7.30M
+18.9% YoY
|
-11.80M
-11.80M – -11.80M
-61.6% YoY
|
-14.10M
-14.10M – -14.10M
-19.5% YoY
|
-9.00M
-9.00M – -9.00M
+36.2% YoY
|
| Net Income |
-31.71M
est: -64.38M (+50.7%)
|
-43.93M
est: -114.03M (+61.5%)
|
-118.61M
est: -239.37M (+50.5%)
|
-91.40M
est: -186.85M (+51.1%)
|
-36.04M
est: -23.42M (-53.9%)
|
-38.09M
est: -28.45M (-33.9%)
|
-27.43M
-27.43M – -27.43M
+3.6% YoY
|
76.21M
76.21M – 76.21M
+377.8% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
21.45M
est: 119.78M (-82.1%)
|
3.52M
est: 93.58M (-96.2%)
|
56.14M
est: 44.92M (+25.0%)
|
58.10M
est: 65.51M (-11.3%)
|
41.54M
est: 50.03M (-17.0%)
|
—
est: 60.04M (-100.0%)
|
48.70M
48.70M – 48.70M
-18.9% YoY
|
78.71M
78.71M – 78.71M
+61.6% YoY
|
94.06M
94.06M – 94.06M
+19.5% YoY
|
60.04M
60.04M – 60.04M
-36.2% YoY
|
| EPS |
-66.40
est: -24.80 (-167.8%)
|
-54.40
est: -43.92 (-23.9%)
|
-125.60
est: -92.19 (-36.2%)
|
-79.20
est: -71.96 (-10.1%)
|
-21.31
est: -8.23 (-158.9%)
|
-13.39
est: -10.00 (-33.9%)
|
-9.64
-9.64 – -9.64
+3.6% YoY
|
26.79
26.79 – 26.79
+377.8% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-30.15M
OE per share TTM
-12.86
Owner's Yield
-183.76%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
16.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-26.4K
Shares Outstanding
2.66M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bent U. Frandsen | Chief Executive Officer | 2M | male |
| Keith Alexander | Chief Financial Officer | — | male |
| Max Sogaard | Chief Scientific Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EXPRS2.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
